MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

Background Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clin...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Current controlled trials in cardiovascular medicine Ročník 20; číslo 1; s. 263 - 13
Hlavní autori:	Uccelli, Antonio, Laroni, Alice, Brundin, Lou, Clanet, Michel, Fernandez, Oscar, Nabavi, Seyed Massood, Muraro, Paolo A., Oliveri, Roberto S., Radue, Ernst W., Sellner, Johann, Soelberg Sorensen, Per, Sormani, Maria Pia, Wuerfel, Jens Thomas, Battaglia, Mario A., Freedman, Mark S.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 09.05.2019 BioMed Central Ltd Springer Nature B.V BMC
Predmet:	Adolescent Adult Analysis Biomedicine Business financing Care and treatment Central nervous system Clinical trial Clinical trials Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Cross-Over Studies Data collection Diagnostic imaging Disability Evaluation Double-Blind Method Double-blind studies Europe Female Good Manufacturing Practice Health Sciences Humans Inflammation Magnetic Resonance Imaging Male Medical research Medicine Medicine & Public Health Mesenchymal Stem Cell Transplantation - adverse effects Mesenchymal stem cells Mesenchymal stromal cells Middle Aged Multicenter Studies as Topic Multiple sclerosis Multiple Sclerosis - diagnostic imaging Multiple Sclerosis - physiopathology Multiple Sclerosis - surgery Nonprofit organizations Randomized Controlled Trials as Topic Recovery of Function Statistics for Life Sciences Stem cell transplantation Stem cells Study Protocol Time Factors Transplantation, Autologous Treatment Outcome Young Adult Europe Italy Spain Mesenchymal stromal cells Clinical trial Multiple sclerosis Mesenchymal stem cells
ISSN:	1745-6215, 1745-6215
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!